Aller au contenu
NOSA – Breathe with care

Relations investisseurs

NOSA, un investissement

NOSA is a world-leading medical technology company in intranasal breathing products, with proprietary technology and production technique that make breathing easier in demanding situations.

0+

markets

>0 %

gross margin

0

products

0

SEK m sales target 2026

Why invest in NOSA?

The company is growing fast

NOSA sells its products in more than 20 markets and is growing fast. The goal is to keep penetrating existing markets while gradually launching new products.

Strong margins

Unique, patented products in a global market. Gross margin is over 63%. The key CAPEX investments in production are already made – the focus now is sales volume, and higher production improves margins further.

Strong finances

EBITDA profitable, aiming to keep growing fast and profitably. In a strong growth phase, strategic investments may occasionally be prioritised over profitability in a single quarter.

Protected technology

Proprietary technology and production technique. All products have patent or trademark protection in strategically selected markets worldwide.

Product portfolio

4 products, all patent or trademark protected

NOSA Odor Control

Against bad odours

NOSA Microbial Control

Against viruses and bacteria in inhaled air

NOSA Smell Training

Smell training kit for people with reduced sense of smell

NOSA Nozoil

Softening nasal spray for dry nasal mucosa – Original and Menthol

Financial targets

Fast, profitable growth

2025–2026

Short term

Growth target
Net sales of at least SEK 50 million in 2026.
Profitability target
Positive EBITDA from Q4 2025 and an EBITDA margin of at least 15 percent in 2026.

2027–2028

Medium term

Growth target
Average organic net sales growth of at least 25 percent per year.
Profitability target
EBITDA margin of at least 18 percent.
Capital structure
Net debt to EBITDA shall not exceed 3 times.
Dividend policy
Surplus is distributed when free cash flow exceeds available investments in profitable growth. Dividends require the capital structure target to be met.

Acquisitions

NOSA aims to expand its portfolio with strong brands to strengthen its market position and make better use of its global distribution network. The company continuously evaluates acquisition opportunities within Ear-Nose-Throat (ENT).

Acquisition criteria

  • Profitable
  • Market leader
  • Strong brand
  • Fits NOSA's portfolio
  • Clear synergies